primelines-nsclc-asco-updates-2017-prime-oncology

SCLC Transformation of EGFR-Mutated NSCLC

Histologic transformation of EGFR-mutant non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a rare mechanism of acquired resistance to EGFR-targeted tyrosine kinase inhibitors (TKIs) that occurs in approximately 3% to 10% of EGFR mutant NSCLCs. However, the natural history and clinical course of SCLC after transformation from NSCLC is poorly understood. […]

Read More

metastatic pleural mesothelioma

Avelumab Active in Advanced Mesothelioma

Malignant plural mesothelioma is a rare, incurable cancer with limited treatment options and poor prognosis. First-line treatment with cisplatin plus pemetrexed is the standard of care, but this is associated with an overall survival (OS) of only 12.1 months. Addition of bevacizumab to this chemotherapy regimen further improves survival in pleural mesothelioma and may be […]

Read More

GnRH Antagonist for Optimal Ovarian Suppression in Breast Cancer

Ovarian function suppression (OFS) is an important part of endocrine treatment for premenopausal women with advanced and early hormone receptor (HR)-positive breast cancer. Achievement of postmenopausal status through OFS is mandatory for treatment with aromatase inhibitors in premenopausal patients. Gonadotropin-releasing hormone (GnRH) agonists (eg, triptorelin, goserelin, leuprolide) are commonly used for ovarian suppression in premenopausal […]

Read More

Breast cancer

Adjuvant T-DM1 New Standard in Early HER2-Positive Breast Cancer

The standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer has evolved significantly in recent years as new agents and combinations have emerged that improve upon standard adjuvant and neoadjuvant treatment with trastuzumab alone. Patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant chemotherapy […]

Read More

FDA Wraps Up 2018 With Approval of Six New Anticancer Indications

2018 was another banner year for approvals by the United States Food and Drug Administration (FDA), with more than 50 new indications being awarded to immunotherapy, targeted therapies, chemotherapies, biosimilar antibodies, and diagnostic tests. Once again, immunotherapy took center stage with new indications for PD-1 and PD-L1 inhibitors across different tumor types. The most notable […]

Read More

Multiple myeloma cells

Daratumumab-Rd Regimen New Standard for Transplant Ineligible Myeloma

  The majority of patients with newly diagnosed multiple myeloma are treated with a triplet of bortezomib, lenalidomide, and dexamethasone (VRd) induction therapy, followed by transplant and maintenance therapy. However, some patients, in particular the elderly, are ineligible for transplant due to frailty or comorbidities. For these patients, treatment with regimens such as VRd or […]

Read More

gut microbiome, melanoma, PD-1

Gut Microbiota Before Bone Marrow Transplantation Predicts Survival

Allogeneic hematopoietic cell transplantation (allo-HCT) is an important treatment for many hematologic malignancies. While this therapy can be life saving for some patients with hematologic cancers, it can be associated with a  complications, including infection, organ toxicity, and graft-versus-host disease (GVHD). The composition of the intestinal microbiota is a known factor influencing toxicity and outcomes […]

Read More

New Data on CAR T-Cell Therapy in Hematologic Malignancies

Chimeric antigen receptor modified (CAR) T cells have emerged in recent years as a novel and highly effective treatment option for patients with different hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). At the 2018 American Society for Hematology (ASH) Annual Meeting, new findings from several […]

Read More

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS

Anemia is a major morbidity associated with low- and intermediate-risk myelodysplastic syndrome (MDS), and patients with MDS often become dependent on red blood cell (RBC) transfusion to counteract symptoms of anemia. Luspatercept, a first-in-class erythroid-maturation agent, is involved in regulation of late stage RBC maturation and is currently being investigated as a treatment for patients […]

Read More